These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30236855)

  • 21. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model.
    Waseda Y; Kobayashi S; Kanda E; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Fujii Y
    Clin Genitourin Cancer; 2020 Apr; 18(2):e62-e70. PubMed ID: 31744700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.
    Ferro M; Vartolomei MD; Russo GI; Cantiello F; Farhan ARA; Terracciano D; Cimmino A; Di Stasi S; Musi G; Hurle R; Serretta V; Busetto GM; De Berardinis E; Cioffi A; Perdonà S; Borghesi M; Schiavina R; Cozzi G; Almeida GL; Bove P; Lima E; Grimaldi G; Matei DV; Crisan N; Muto M; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Shariat S; Mirone V; Lucarelli G
    World J Urol; 2019 Mar; 37(3):507-514. PubMed ID: 29992381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour.
    Suarez-Ibarrola R; Soria F; Abufaraj M; D'Andrea D; Preto M; Gust KM; Briganti A; Shariat SF; Gontero P
    BJU Int; 2019 Apr; 123(4):646-650. PubMed ID: 30248235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.
    Sörenby A; Baseckas G; Bendahl PO; Brändstedt J; Håkansson U; Nilsson S; Patschan O; Tinzl M; Wokander M; Liedberg F; Gudjonsson S
    Scand J Urol; 2019; 53(2-3):109-115. PubMed ID: 31064253
    [No Abstract]   [Full Text] [Related]  

  • 28. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study.
    Liedberg F; Hagberg O; Holmäng S; Hosseini Aliabad A; Jancke G; Ljungberg B; Malmström PU; Åberg H; Jahnson S
    Scand J Urol; 2015; 49(4):290-5. PubMed ID: 25624049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Bosschieter J; Nieuwenhuijzen JA; van Ginkel T; Vis AN; Witte B; Newling D; Beckers GMA; van Moorselaar RJA
    Eur Urol; 2018 Feb; 73(2):226-232. PubMed ID: 28705539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The intravesical recurrence after 3-day consecutive intravesical instillation of pirarubicine hydrochloride (THP) following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer].
    Tochigi T; Sakurada Y; Aoki H; Kawamura S; Itou S; Satou I; Tateno H
    Nihon Hinyokika Gakkai Zasshi; 2012 Jul; 103(4):610-6. PubMed ID: 23120995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
    Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
    Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
    Elsawy AA; El-Assmy AM; Bazeed MA; Ali-El-Dein B
    Urol Oncol; 2019 Mar; 37(3):179.e9-179.e18. PubMed ID: 30448030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study.
    Li NC; Ye ZQ; Na YQ;
    Chin Med J (Engl); 2013; 126(15):2805-9. PubMed ID: 23924446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.
    Thiel T; Ryk C; Renström-Koskela L; Steineck G; Schumacher MC; Wiklund NP; de Verdier PJ
    World J Urol; 2019 Jan; 37(1):155-163. PubMed ID: 29905887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.
    Madeb R; Golijanin D; Noyes K; Fisher S; Stephenson JJ; Long SR; Knopf J; Lyman GH; Messing EM
    Cancer; 2009 Jun; 115(12):2660-70. PubMed ID: 19455607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.